GKOS Glaukos Corporation
USHealthcareAs of 2026-10-07 11:28
Why GKOS matters now
Glaukos Corporation (GKOS) is a US stock in Healthcare. The latest InvestLog snapshot shows $172.70 with +6.88% on the session and $10.19B in market capitalization; recent performance reads 1-month -6.59% and YTD +15.74%.
The latest financial table shown here is Q1 2026, with revenue of $150.6M, net income of $-19.8M, and EPS of $-0.34. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.2%.
The latest indexable market news headline is "Glaukos says late-stage eye disease treatment shows lasting benefits after single dose" from Reuters.
Additional event context on this page matters because analyst consensus is Buy with a median target of $147.50; recent insider activity includes Navratil Tomas filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
11.30
P/S
13.92
EV/EBITDA
-53.29
DCF Value
$-79.00
FCF Yield
-0.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
78.1%
Operating Margin
-15.6%
Net Margin
-34.3%
ROE
-26.5%
ROA
-21.2%
ROIC
-10.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $150.6M | $-19.8M | $-0.34 |
| Q4 2025 | $143.1M | $-133.7M | $-2.32 |
| FY 2025 | $507.4M | $-187.7M | $-3.28 |
| Q3 2025 | $133.5M | $-16.2M | $-0.28 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$151.25
Target (Median)
$147.50
Target Range
$135.00 - $170.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.81
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.